share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Biodexa Pharmaceuticals | 6-K:外國發行人報告

美股sec公告 ·  2023/12/29 13:00
牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced the appointment of Ann Merchant as a Non-executive Director to its Board of Directors, effective December 31, 2023. Merchant brings extensive experience from her current role as Vice President and Head of Global Supply Chain and External Operations at MorphoSys AG, and her previous position as President of Schreiner Medipharm. She has also held various roles at Amgen Inc., including Vice President and Head of International Supply Chain. Merchant, who holds an MBA from Henley Business School and a Bachelor of Science from Georgetown University, is also on the board of Alvotech S.A. Her term as a director at Biodexa Pharmaceuticals is set to expire at the company's annual general...Show More
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced the appointment of Ann Merchant as a Non-executive Director to its Board of Directors, effective December 31, 2023. Merchant brings extensive experience from her current role as Vice President and Head of Global Supply Chain and External Operations at MorphoSys AG, and her previous position as President of Schreiner Medipharm. She has also held various roles at Amgen Inc., including Vice President and Head of International Supply Chain. Merchant, who holds an MBA from Henley Business School and a Bachelor of Science from Georgetown University, is also on the board of Alvotech S.A. Her term as a director at Biodexa Pharmaceuticals is set to expire at the company's annual general meeting in 2026. In addition to her directorship, Merchant is expected to be granted options to acquire one percent of the company's outstanding ordinary shares and to serve on the audit and remuneration committees. The appointment is part of a Form 6-K filing with the SEC for December 2023, which also includes a press release dated December 29, 2023.
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC宣佈任命安·默特爲董事會非執行董事,自2023年12月31日起生效。Merchant目前在MorphoSys AG擔任副總裁兼全球供應鏈和外部運營負責人,以及之前擔任Schreiner Medipharm總裁期間,她帶來了豐富的經驗。她還曾在安進公司擔任過各種職務,包括副總裁兼國際供應鏈主管。Merchant擁有亨利商學院工商管理碩士學位和喬治敦大學理學學士學位,也是Alvotech S.A的董事會成員。她作爲Biodexa Pharmicals董事的任期將在2026年的公司年度股東大會上屆滿。除了董事職位外,預計Merchant還將獲得收購公司百分之一的已發行普通股並在審計和薪酬委員會任職的期權。該任命是向美國證券交易委員會提交的2023年12月6-K表格的一部分,其中還包括2023年12月29日的新聞稿。
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC宣佈任命安·默特爲董事會非執行董事,自2023年12月31日起生效。Merchant目前在MorphoSys AG擔任副總裁兼全球供應鏈和外部運營負責人,以及之前擔任Schreiner Medipharm總裁期間,她帶來了豐富的經驗。她還曾在安進公司擔任過各種職務,包括副總裁兼國際供應鏈主管。Merchant擁有亨利商學院工商管理碩士學位和喬治敦大學理學學士學位,也是Alvotech S.A的董事會成員。她作爲Biodexa Pharmicals董事的任期將在2026年的公司年度股東大會上屆滿。除了董事職位外,預計Merchant還將獲得收購公司百分之一的已發行普通股並在審計和薪酬委員會任職的期權。該任命是向美國證券交易委員會提交的2023年12月6-K表格的一部分,其中還包括2023年12月29日的新聞稿。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。